Skip to main content
Erschienen in: The Journal of Headache and Pain 1/2018

Open Access 01.12.2018 | Editorial

Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?

verfasst von: Messoud Ashina, Paolo Martelletti

Erschienen in: The Journal of Headache and Pain | Ausgabe 1/2018

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Since its discovery in 1989 [1], pituitary adenylate cyclase activating peptide (PACAP) has emerged as a key molecule in primary headaches. New insights on the role of PACAP in migraine [2] have now been translated into interest in exploring the migraine preventative effect of monoclonal antibodies against PACAP and monoclonal antibodies against PAC1 receptor (https://​clinicaltrials.​gov/​ct2/​show/​NCT03238781?​term=​AMG301&​rank=​1 ;[3]).
Given that PACAP is a multifunctional peptide involved in various cellular and physiological responses, it is important to understand and further explore its function in non-headache mechanisms which might be relevant in context to primary headaches. This TJHP thematic series provide an overview of the history of the discovery of PACAP and its three receptors [4] and summarize PACAP and its receptor distribution in migraine relevant structures [5]. Furthermore, the readers will get insights on the role of PACAP in regulating the production of inflammatory mediators [6] and important role of degranulation of dural mast cells via a yet unknown receptor in migraine induction by PACAP38 [7]. The series also cover possible mechanisms of PACAP38-induced migraine, outline future directions [8] and discuss how PACAP may cross the blood brain barrier [9] and its implication for PACAP induced migraine. To further elucidate the role of PACAP in primary headaches it is important to study its role in regulation of sleep [10] and vascular tone [11] which are covered by excellent review articles in the special issue Both aspects are important in context of tolerability and safety of future anti PACAP drugs for prevention of primary headaches. Altogether our aim is to provide a comprehensive series of reviews focusing on PACAP as an emerging molecule in primary headache headaches.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Miyata A, Jiang L, Dahl RD et al (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643–648CrossRefPubMed Miyata A, Jiang L, Dahl RD et al (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643–648CrossRefPubMed
9.
Zurück zum Zitat Amin FM, Winther Schytz H. Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine. Amin FM, Winther Schytz H. Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine.
Metadaten
Titel
Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?
verfasst von
Messoud Ashina
Paolo Martelletti
Publikationsdatum
01.12.2018
Verlag
Springer Milan
Erschienen in
The Journal of Headache and Pain / Ausgabe 1/2018
Print ISSN: 1129-2369
Elektronische ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-018-0860-4

Weitere Artikel der Ausgabe 1/2018

The Journal of Headache and Pain 1/2018 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.